Valuation: Fortress Biotech, Inc.

Market Cap 95.72M 81.99M 76.72M 70.23M 132M 9.16B 134M 906M 353M 4.6B 359M 352M 15.22B P/E 2026 *
1.2x
P/E 2027 * -5.74x
Enterprise Value 95.72M 81.99M 76.72M 70.23M 132M 9.16B 134M 906M 353M 4.6B 359M 352M 15.22B EV / Sales 2026 *
1.2x
EV / Sales 2027 * 0.78x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day+3.61%
1 week-2.05%
Current month-8.31%
1 month-19.15%
3 months+4.74%
6 months-14.58%
Current year-21.58%
1 week 2.73
Extreme 2.7301
2.93
1 month 2.57
Extreme 2.57
3.5
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
6.5
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 2013-12-19
Director of Finance/CFO 51 2012-02-21
Director of Finance/CFO 36 2022-08-15
Director TitleAgeSince
Director/Board Member 74 2008-11-30
Chairman 71 2013-12-19
Director/Board Member 63 2006-05-31
Date Insider Type Main position Quantity % Market Cap.
1/1/26 Free

Director

27,322 0.0880%
1/1/26 Free

Director

27,322 0.0880%
1/1/26 Free

Director

27,322 0.0880%
Change 5-day change 1-year change 3-year change Capi.($)
+3.61%-2.05%+26.43%-55.19% 95.72M
+0.90%+3.80%+41.49%-0.78% 83.28B
+8.86%+129.20%+435.14%+24.85% 57.92B
-1.69%+23.30%-22.30%-36.29% 57.77B
-1.46%+0.19%-2.06%+30.50% 51.75B
+1.74%+4.43%+12.37%+169.64% 49.35B
+1.13%+3.31%+55.61%-17.57% 32.03B
+0.46%+6.37%+50.29%+97.27% 25.91B
+1.19%+9.17%+2.97%+230.86% 22.74B
-0.30%+4.45%+58.29%+118.84% 16.87B
Average +1.44%+18.22%+65.82%+56.21% 39.77B
Weighted average by Cap. +1.44%+24.96%+80.49%+46.35%

Financials

2026 *2027 *
Net sales 79.88M 68.42M 64.02M 58.6M 110M 7.64B 111M 756M 295M 3.84B 300M 293M 12.7B 123M 105M 98.58M 90.24M 169M 11.77B 172M 1.16B 454M 5.91B 462M 452M 19.55B
Net income 90.51M 77.53M 72.55M 66.41M 125M 8.66B 126M 857M 334M 4.35B 340M 332M 14.39B -20.84M -17.85M -16.7M -15.29M -28.69M -1.99B -29.07M -197M -76.95M -1B -78.24M -76.54M -3.31B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
26-08-21 US$2.870 +3.61% 202,715
26-08-20 US$2.770 -2.81% 323,758
26-08-19 US$2.850 -2.06% 536,559
26-08-18 US$2.910 +3.19% 593,190
26-08-17 US$2.820 -3.75% 838,776
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.870USD
Average target price
11.00USD
Spread / Average Target
+283.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock